Specialized Metrics to Properly Assess AI-Pharma Startups
Published: | Updated:
AI-Pharma companies are 100 times as complex as FinTech companies. Methodologies used to assess them should be 100 times as rigorous, writes Margaretta Colangelo.
Dmitry Kaminskiy
Advertisement
Dmitry Kaminskiy is General Partner, Deep Knowledge Ventures
Articles by Dmitry Kaminskiy
Advertisement
Latest Updated Articles
Specialized Metrics to Properly Assess AI-Pharma StartupsPublished: April 18th 2019 | Updated: November 15th 2020
Advertisement
Advertisement
Trending on PharmExec
1
The Influence of Trump Rx in Pharmacy Benefit Managers, Retail Pharmacies, and Digital Health Platforms
2
Leading in the Psychedelic Space: Q&A with Tarek Rabah
3
Bringing HIV Prevention DTC: Q&A with Ashley Gildea
4
Boehringer Ingelheim Acquires Exclusive License from Sitryx Therapeutics for Preclinical Small Molecule Program
5